SV1996000006A - Purin-6-onas bisustituidas en 2,9 - Google Patents

Purin-6-onas bisustituidas en 2,9

Info

Publication number
SV1996000006A
SV1996000006A SV1996000006A SV1996000006A SV1996000006A SV 1996000006 A SV1996000006 A SV 1996000006A SV 1996000006 A SV1996000006 A SV 1996000006A SV 1996000006 A SV1996000006 A SV 1996000006A SV 1996000006 A SV1996000006 A SV 1996000006A
Authority
SV
El Salvador
Prior art keywords
bisustituted
onas
purin
purina
diseases
Prior art date
Application number
SV1996000006A
Other languages
English (en)
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV1996000006A publication Critical patent/SV1996000006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON LA OBTENCION DE PURIN-6-ONAS BISUSTITUIDAS EN 2,9, ACILANDO EN UNA PRIMERA ETAPA LOS CORRESPONDIENTES AMINOIMIDAZOLES SSUTITUIDOS CORRESPONDIENTES Y CILANDO, DESPUES DE ESTO, PARA OBTENERLA PURINA, LAS NUEVAS PURIN-6-ONAS BISUSTITUIDAS EN 2,9 PUEDEN EMPLEARSE COMO SUSTANCIAS ACTIVA EN MEDICAMENTO, ESPECIALMENTE PARA EL TRATAMIENTO DEINFLAMACIONES, ENFERMEDADES TRIOMBOEMBOLICAS, DEL CORAZON Y DE LA CIRCULACION Y ENFERMEDADES DEL SISTEMA UROGENITAL.
SV1996000006A 1995-01-19 1996-01-19 Purin-6-onas bisustituidas en 2,9 SV1996000006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
SV1996000006A true SV1996000006A (es) 1996-10-29

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1996000006A SV1996000006A (es) 1995-01-19 1996-01-19 Purin-6-onas bisustituidas en 2,9

Country Status (31)

Country Link
US (1) US5861404A (es)
EP (1) EP0722944A1 (es)
JP (1) JPH08231545A (es)
KR (1) KR960029334A (es)
CN (1) CN1135485A (es)
AR (1) AR002953A1 (es)
AU (1) AU4097996A (es)
BG (1) BG61728B1 (es)
BR (1) BR9600147A (es)
CA (1) CA2167353A1 (es)
CO (1) CO4700523A1 (es)
CZ (1) CZ16696A3 (es)
DE (1) DE19501482A1 (es)
EE (1) EE9600018A (es)
FI (1) FI960225A (es)
HR (1) HRP960007A2 (es)
HU (1) HUP9600106A3 (es)
IL (1) IL116769A (es)
MA (1) MA23778A1 (es)
NO (1) NO960223L (es)
NZ (1) NZ280830A (es)
PE (1) PE64996A1 (es)
PL (1) PL312354A1 (es)
SG (1) SG50401A1 (es)
SK (1) SK8096A3 (es)
SV (1) SV1996000006A (es)
TN (2) TNSN96006A1 (es)
TR (1) TR199600028A2 (es)
TW (1) TW314519B (es)
YU (1) YU1396A (es)
ZA (1) ZA96398B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
ES2222614T3 (es) * 1997-11-12 2005-02-01 Mitsubishi Chemical Corporation Derivados de purina y medicina que los contiene como ingrediente activo.
USRE39112E1 (en) * 1998-01-05 2006-05-30 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
KR100747106B1 (ko) * 1999-05-11 2007-08-08 미쯔비시 가가꾸 가부시끼가이샤 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
WO2002020058A1 (fr) * 2000-09-06 2002-03-14 Tanabe Seiyaku Co., Ltd. Preparations administrees par voie orale
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
HUP9600106A3 (en) 1998-04-28
FI960225A (fi) 1996-07-20
NO960223L (no) 1996-07-22
FI960225A0 (fi) 1996-01-17
MA23778A1 (fr) 1996-10-01
DE19501482A1 (de) 1996-07-25
CO4700523A1 (es) 1998-12-29
US5861404A (en) 1999-01-19
BG61728B1 (bg) 1998-04-30
TR199600028A2 (tr) 1996-08-21
EP0722944A1 (de) 1996-07-24
PL312354A1 (en) 1996-07-22
EE9600018A (et) 1996-08-15
JPH08231545A (ja) 1996-09-10
ZA96398B (en) 1996-08-28
IL116769A0 (en) 1996-05-14
NZ280830A (en) 1998-04-27
AU4097996A (en) 1996-07-25
IL116769A (en) 1998-12-06
TW314519B (es) 1997-09-01
NO960223D0 (no) 1996-01-18
BG100292A (bg) 1996-07-31
HU9600106D0 (en) 1996-03-28
CZ16696A3 (en) 1996-08-14
HUP9600106A2 (en) 1997-05-28
CA2167353A1 (en) 1996-07-20
BR9600147A (pt) 1998-01-06
HRP960007A2 (en) 1998-02-28
TNSN96006A1 (fr) 2005-03-15
PE64996A1 (es) 1997-03-09
CN1135485A (zh) 1996-11-13
AR002953A1 (es) 1998-05-27
KR960029334A (ko) 1996-08-17
TNSN96007A1 (fr) 2005-03-15
SG50401A1 (en) 1998-07-20
YU1396A (sh) 1999-03-04
SK8096A3 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
SV1996000006A (es) Purin-6-onas bisustituidas en 2,9
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ATE55258T1 (de) Arzneimittelenthaltende matrizen fuer einfuehrungen in zonen mit cellularen lesionen.
HUP9900800A2 (hu) Szerves vegyületeket tartalmazó készítmények
JPS52102419A (en) Lactic acid producing bacillus preparation
SE8802675L (sv) Terapeutiska ringar
ES2147320T3 (es) Derivados de n-(3-benzofuranil)urea.
ES2170884T3 (es) Acidos alfa-iminohidroxamicos y carboxilicos n-sustituidos, ciclicos y heterociclicos.
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
AR032293A1 (es) Estuche farmaceutico
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
SE7902742L (sv) Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
DE3781652D1 (de) Zubereitung, geeignet fuer die behandlung von darmstoerungen.
CO4700524A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9 sustituidas
ES2067520T3 (es) Antibioticos y procedimiento para su produccion.
DE3764559D1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
ES2039460T3 (es) Un procedimiento para producir una solucion inyectable de glicosido de antraciclina.
ES2148600T3 (es) Derivados de indol sustituidos.
NO167739C (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive ginkolid-derivater.
DE3883044D1 (de) Wirkstoff zur tumorbekaempfung.
ECSP961642A (es) Purin-6- onas bisustituidas en 2,9'' lea 30700-ec
SU651805A1 (ru) Способ лечени заболеваний роговицы
SU542514A1 (ru) Способ лечени нефроптоза
AR240063A1 (es) Procedimiento para la produccion del activador del plasminogeno del tejido humano mediante el cultivo de la cepa de celulas registrada como kym-sf ifo 50135.